Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Artru

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 18, 2024
Rectal cancer - French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR, and GRECCAR)Eddy Cotte, Justine Arquilliere, Pascal Artru, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 30, 2015
Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodologyMomar Diouf, Thomas Filleron, Anne-Laure Pointet, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)Isabelle Trouilloud, Anne-Claire Dupont-Gossard, David Malka, et al.
JAMA Oncology|September 1, 2022
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical TrialThierry Conroy, Florence Castan, Anthony Lopez, et al.
Clinical Colorectal Cancer|November 13, 2018
Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE TrialJaafar Bennouna, Thierry André, Loïc Campion, et al.
Clinical Colorectal Cancer|September 28, 2024
Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer PatientsIrene Assaf, Giacomo Bregni, Geraldine Anthoine, et al.
Therapeutic Advances in Gastroenterology|October 11, 2019
Folfirinox <i>versus</i> gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score studyNicolas Williet, Angélique Saint, Anne-Laure Pointet, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 10, 2024
Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessmentEric François, Nicolas Magné, Rabia Boulahssass, et al.
International Journal of Cancer|December 23, 2022
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO studyMarie Auvray Kuentz, Vincent Hautefeuille, Louis de Mestier, et al.
Journal of the National Cancer Institute|August 20, 2025
Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter studyAziz Zaanan, Elisabeth Sophie Bergen, Ludovic Evesque, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 18, 2024
Rectal cancer - French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR, and GRECCAR)Eddy Cotte, Justine Arquilliere, Pascal Artru, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 30, 2015
Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodologyMomar Diouf, Thomas Filleron, Anne-Laure Pointet, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)Isabelle Trouilloud, Anne-Claire Dupont-Gossard, David Malka, et al.
JAMA Oncology|September 1, 2022
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical TrialThierry Conroy, Florence Castan, Anthony Lopez, et al.
Clinical Colorectal Cancer|November 13, 2018
Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE TrialJaafar Bennouna, Thierry André, Loïc Campion, et al.
Clinical Colorectal Cancer|September 28, 2024
Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer PatientsIrene Assaf, Giacomo Bregni, Geraldine Anthoine, et al.
Therapeutic Advances in Gastroenterology|October 11, 2019
Folfirinox <i>versus</i> gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score studyNicolas Williet, Angélique Saint, Anne-Laure Pointet, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 10, 2024
Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessmentEric François, Nicolas Magné, Rabia Boulahssass, et al.
International Journal of Cancer|December 23, 2022
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO studyMarie Auvray Kuentz, Vincent Hautefeuille, Louis de Mestier, et al.
Journal of the National Cancer Institute|August 20, 2025
Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter studyAziz Zaanan, Elisabeth Sophie Bergen, Ludovic Evesque, et al.
Pageof 9